antibacterial therapy News and Research

RSS

Microneedle bandage offers new hope for diabetic wound treatment

Researchers developed a microneedle (MN) bandage containing selenium (Se) and chlorin e6 (Ce6) hybrid nanoparticles (SeC@PA) for diabetic wound therapy.

28 Nov 2023

How were antibiotics used during the COVID-19 pandemic?

Researchers explores the application of antimicrobial stewardship in the antibiotic prescribing guidelines during the COVID-19 pandemic.

11 Oct 2023

Phico Therapeutics awarded up to $18.2 million USD (c.£13.2 million GBP) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials

Phico Therapeutics has been awarded a grant of up to $18.2 million USD to tackle the global rising threat of drug-resistant bacteria.

From Phico Therapeutics 19 Apr 2021

Are antibiotic regimens for critical COVID-19 patients with bacterial superinfection unnecessarily high?

A new study by researchers at Northwestern University Feinberg School of Medicine, USA, shows that antibiotic regimens for critically ill COVID-19 patients with bacterial superinfections may be promoting an unnecessarily high.

19 Jan 2021

Innovative antibacterial solution enables professional-level dental hygiene at home

Elective dental procedures have been restricted globally due to the Covid-19 pandemic. Novel innovation enables professional-level oral hygiene at home.

11 May 2020

KU Leuven researchers develop new antibacterial strategy that weakens bacteria

Bioscience engineers from KU Leuven in Belgium have developed a new antibacterial strategy that weakens bacteria by preventing them from cooperating. Unlike with antibiotics, there is no resistance to this strategy, because the non-resistant bacteria outnumber resistant ones.

14 Jan 2020

Phage engineering gives antibacterial therapy a new lease of life

Researchers have been identifying and modifying known phages to fight against infectious bacteria.

4 Oct 2019

Researchers uncover how insect antibiotic targets Gram-negative bacteria

An antibiotic called thanatin attacks the way the outer membrane of Gram-negative bacteria is built. Researchers at the University of Zurich have now found out that this happens through a previously unknown mechanism. Thanatin, produced naturally by the spined soldier bug, can therefore be used to develop new classes of antibiotics.

15 Nov 2018

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

21 Mar 2016

Researchers discover new approach to tackle global threat of antibiotic drug resistance

Researchers at McMaster University are addressing the crisis in drug resistance with a novel approach to find new antibiotics.

13 Oct 2013

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).

10 Sep 2012

Atox Bio to advance AB103 Phase 2 study with $3.25M financing

Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).

19 Dec 2011

Researchers identify new method to tackle bacterial infections

Researchers from the University of Groningen have clarified the structure of an enzyme that disturbs the communication processes between bacteria. By doing so they have laid the foundations for a new method of tackling bacterial infections such as cystic fibrosis.

22 Dec 2009

Cempra commences Phase 2/3 clinical study of CEM-102 for treating acute bacterial skin structure infections

Cempra Pharmaceuticals today announced that enrollment is underway in an adaptive design Phase 2/3 clinical study with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). CEM-102 is an oral antibiotic with an established record of treating staphylococcal infections outside the United States, including those due to methicillin-resistant Staphylococcus aureus (MRSA).

10 Sep 2009

FDA approves new indication for Wyeth's Tygacil (tigecycline)

Wyeth Pharmaceuticals, a division of Wyeth has announced that the U.S. Food and Drug Administration (FDA) approved Tygacil (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens.

24 Mar 2009

Vaginal probiotic product reduce recurrence rate of bacterial vaginosis

A newly published double blind, randomised, placebo controlled study(1) shows that EcoVag, a patented vaginal probiotic product from the Danish company, Bifodan, significantly reduces the recurrence rate of Bacterial Vaginosis (BV) following antibiotic treatment.

31 Jan 2008